Anavex Life Sciences Corp (AVXL)

[TTTav66]

Update: Anavex's presentation, Systematic Processing of Full Genomic Analysis of ANAVEX®2-73 Phase 2a Alzheimer’s Disease Study Identifies Biomarkers Enabling a Precision Medicine Approach has been moved from its original timeslot of 5:15-5:30 on 7/25 to 3:00-3:15 on the same day.

It is now grouped into Developing Topics: Recent Developments in Therapeutics which runs from 2:00-4:00 and features 7 oral presentations. The final presentation of the session, getting a half hour timeslot from 3:30-4:00 will be Biogen/Eisai's, Treatment of Early AD subjects with BAN2401, an Anti-Aß Protofibril Monoclonal Antibody, Significantly Clears Amyloid Plaque and Reduces Clinical Decline.